If your cancer has specific gene mutations and isn’t responding to certain hormone therapies,
Images do not represent the actual size of the tablets.
Testing is key to finding HRR gene mutations such as BRCA1, BRCA2, and ATM mutations, which were present in 28% of patients with this unique type of metastatic prostate cancer in a study. The presence of HRR gene mutations in your tumor may inform a treatment journey.
Mutations can be acquired or inherited. Testing could also show if people in your family might be at risk of developing cancer.
The data below are a subset of a larger study that tested a total of 387 men who had 1 or more of 15† HRR genetic tumor mutations and metastatic castration-resistant prostate cancer (mCRPC) after they were no longer responding to hormone therapies enzalutamide or abiraterone. The subset consisted of 245 men with BRCA1, BRCA2, or ATM gene mutations. 162 men took LYNPARZA 300 mg twice daily and 83 took hormone therapies enzalutamide or abiraterone.
2X *LYNPARZA more than doubled the median without cancer progressing or death compared to treatment with hormone therapies enzalutamide or abiraterone.
2X
*LYNPARZA more than doubled the median time without cancer progressing or death compared to treatment with hormone therapies enzalutamide or abiraterone.
56 out of 162 men did not have disease progression or death with LYNPARZA vs 15 out of 83 men on enzalutamide or abiraterone.
†In addition to BRCA1, BRCA2, and ATM, other HRR genes included BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. No patients were included who had mutations in 2 of the 15 pre-specified HRR genes: FANCL and RAD51C. Although patients with mutations in PPP2R2A were studied, LYNPARZA is not indicated for the treatment of patients with this gene mutation.
These data are a secondary conclusion, or result, of the overall study.
In this subset, 71 out of 162 patients treated with LYNPARZA were alive at the time of follow-up compared to 26 out of 83 treated with enzalutamide or abiraterone.
The median time of survival after the start of LYNPARZA was 19.1 months vs 14.7 months on enzalutamide or abiraterone.
LOWER RISK OF DEATH
These data are a secondary conclusion, or result, of the overall study.
In this subset, 71 out of 162 patients treated with LYNPARZA were alive at the time of follow-up compared to 26 out of 83 treated with enzalutamide or abiraterone.
The median time of survival after the start of LYNPARZA was 19.1 months vs 14.7 months on enzalutamide or abiraterone.
VS
These data are a secondary conclusion, or result, of the overall study, and are based on 127 patients. 28 out of 84 men responded to LYNPARZA vs 1 out of 43 on enzalutamide or abiraterone.
VS
These data are a secondary conclusion, or result, of the overall study, and are based on 127 patients. 28 out of 84 men responded to LYNPARZA vs 1 out of 43 on enzalutamide or abiraterone.
The data below are a secondary conclusion, or result, of the overall study, which tested a total of 387 men who had 1 or more of 15* HRR genetic tumor mutations and metastatic castration-resistant prostate cancer (mCRPC) after they were no longer responding to hormone therapies enzalutamide or abiraterone. 256 men took LYNPARZA 300 mg twice daily and 131 took hormone therapies enzalutamide or abiraterone.
LYNPARZA increased the median time without cancer progressing or death compared to treatment with hormone therapies enzalutamide or abiraterone.
76 out of 256 men did not have disease progression or death with LYNPARZA vs 32 out of 131 men on enzalutamide or abiraterone.
*In addition to BRCA1, BRCA2, and ATM, other HRR genes included BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. No patients were included who had mutations in 2 of the 15 pre-specified HRR genes: FANCL and RAD51C. Although patients with mutations in PPP2R2A were studied, LYNPARZA is not indicated for the treatment of patients with this gene mutation.
If your doctor has prescribed LYNPARZA, you may have questions. The AstraZeneca Access 360TM program can help. We can answer your questions about insurance coverage, out-of-pocket costs, and patient assistance programs. To learn more about the Access 360 program, please call 1-844-ASK-A360 (1-844-275-2360) Monday-Friday 8 AM-8 PM ET, or visit www.MyAccess360.com.
This is based on commercially insured patients. The average monthly cost for LYNPARZA may be greater than $0 for some patients.
If you have any questions about LYNPARZA, speak with one of our specially trained nurses.
To speak with a nurse, call 1-800-770-8337.
LYNPARZA can fit into your daily routine. You can take LYNPARZA with you wherever you go. It’s two tablets (150 mg each), taken by mouth in the morning and in the evening, with or without food, totaling four tablets each day (600 mg daily dose).
Take doses 12 hours apart with or without food.
Images do not represent the actual tablet size of the tablets.
If you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).
Foods to avoidAvoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
If you miss a doseTake your next dose at the usual scheduled time. Do not take an extra dose to make up for the one you missed.
If you take too muchCall your doctor or go to the nearest hospital emergency room right away.
Each treatment plan is unique and any questions you might have should be discussed with your doctor.
Learn about how LYNPARZA works, data from clinical trials, side effects, and dosing information.
DOWNLOAD
Prostate Cancer Patient Brochure
Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.
DOWNLOAD
Tips for Managing Your Treatment Brochure
Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.
DOWNLOAD
LYNPARZA Caregiver Brochure
Your submission was successful.
LYNPARZA is a prescription medicine used to treat adults who have:
It is not known if LYNPARZA is safe and effective in children.
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:
Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.
Blood clots (Venous Thromboembolic Events). Some people with prostate cancer who take LYNPARZA along with gonadotropin-releasing hormone (GnRH) analog therapy may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lung (pulmonary embolism). Tell your healthcare provider if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?
What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:
These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.
You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088 .
Please click here for complete Prescribing Information, including Patient Information (Medication Guide).
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
